pharmaphorum6d
FDA approves Sanofi colon cancer drug, Zaltrap
Zaltrap, developed by Sanofi and Regeneron Pharmaceuticals, will compete with Roche Holding AG’s Avastin (bevacizumab) and Bristol-Myers Squibb Co's Erbitux (cetuximab). Vertex's gene-editing ...
Regeneron: Strong Buy Rating Driven by Dupixent’s Growth and Promising Pipeline Developments
Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...
Business Insider23d
Regeneron Faces Sell Rating Amid Eylea’s Underperformance and Competitive Threats from Amgen’s Pavblu
Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. Read More on REGN: Regeneron Pharmaceuticals NewsMORE Related Stocks ...
Reuters24d
Truveta sells stakes to Regeneron, Illumina in deal to build genetic database
NEW YORK, Jan 13 (Reuters) - Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals (REGN.O), opens new tab, Illumina (ILMN.O), opens new ...